Titel

Merkliste
1 Ergebnisse

Impact of methodological choices in comparative effectivene..:

Lefort, M ; Sharmin, S ; Andersen, J...
info:eu-repo/semantics/altIdentifier/doi/10.1186/s12874-022-01623-8. , 2022

Link: https://univ-rennes.hal.science/hal-03690493

RT Journal
T1 <Title>Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftunivrennes2hal:oai:HAL:hal-03690493v1&Exemplar=1&LAN=DE
				
A1 Lefort, M
A1 Sharmin, S
A1 Andersen, J
A1 Vukusic, S
A1 Casey, R
A1 Debouverie, M
A1 Edan, G
A1 Ciron, J
A1 Ruet, A
A1 de Sèze, J
A1 Maillart, E
A1 Zephir, H
A1 Labauge, P
A1 Defer, G
A1 Lebrun-Frenay, C
A1 Moreau, T
A1 Berger, E
A1 Clavelou, P
A1 Pelletier, J
A1 Stankoff, B
A1 Gout, O
A1 Thouvenot, Eric
A1 Heinzlef, O
A1 Al-Khedr, A
A1 Bourre, B
A1 Casez, O
A1 Cabre, P
A1 Montcuquet, A
A1 Wahab, A
A1 Camdessanché, J
A1 Maurousset, A
A1 Ben Nasr, H
A1 Hankiewicz, K
A1 Pottier, C
A1 Maubeuge, N
A1 Dimitri-Boulos, D
A1 Nifle, C
A1 Laplaud, D
A1 Horakova, D
A1 Havrdova, E
A1 Alroughani, R
A1 Izquierdo, G
A1 Eichau, S
A1 Ozakbas, S
A1 Patti, F
A1 Onofrj, M
A1 Lugaresi, A
A1 Terzi, M
A1 Grammond, P
A1 Grand'Maison, F
A1 Yamout, B
A1 Prat, A
A1 Girard, M
A1 Duquette, P
A1 Boz, C
A1 Trojano, M
A1 Mccombe, P
A1 Slee, M
A1 Lechner-Scott, J
A1 Turkoglu, R
A1 Sola, P
A1 Ferraro, D
A1 Granella, F
A1 Shaygannejad, V
A1 Prevost, J
A1 Maimone, D
A1 Skibina, O
A1 Buzzard, K
A1 van Der Walt, A
A1 Karabudak, R
A1 van Wijmeersch, B
A1 Csepany, T
A1 Spitaleri, D
A1 Vucic, S
A1 Koch-Henriksen, N
A1 Sellebjerg, F
A1 Soerensen, P
A1 Hilt Christensen, C
A1 Rasmussen, P
A1 Jensen, M
A1 Frederiksen, J
A1 Bramow, S
A1 Mathiesen, H
A1 Schreiber, K
A1 Butzkueven, H
A1 Magyari, M
A1 Kalincik, T
A1 Leray, Emmanuelle
PB HAL CCSD; BioMed Central
YR 2022
K1 Causal contrasts
K1 Censoring
K1 Effectiveness
K1 Indication bias
K1 Multiple sclerosis
K1 Positivity assumption
K1 Propensity score
K1 MESH: Fingolimod Hydrochloride
K1 MESH: Humans
K1 MESH: Multiple Sclerosis
K1 Relapsing-Remitting
K1 MESH: Natalizumab
K1 MESH: Treatment Outcome
K1 [SDV]Life Sciences [q-bio]
JF info:eu-repo/semantics/altIdentifier/doi/10.1186/s12874-022-01623-8
LK http://dx.doi.org/https://univ-rennes.hal.science/hal-03690493
DO https://univ-rennes.hal.science/hal-03690493
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)